
1. vaccine. 2016 jun 3;34(26):2967-2970. doi: 10.1016/j.vaccine.2016.02.077. epub
2016 mar 11.

status research development vaccines enterovirus 71.

reed z(1), cardosa mj(2).

author information: 
(1)clinical development consultant, 26 rue lecourbe, paris 75015, france.
electronic address: zahussain22@gmail.com.
(2)sentinext therapeutics, 19h level 19, menara northam, 55, jalan sultan ahmad
shah, 10050 george town, pulau pinang, malaysia.

although outbreaks hand, foot, mouth disease (hfmd) young children have
long recognized worldwide, occurrence rare life-threatening
neurological, respiratory, cardiac complications propelled common
condition spotlight major public health problem affected
countries. various enteroviruses cause hfmd, severe complications have
been mostly associated enterovirus 71 (ev71). medical treatment is
supportive measures interrupt transmission challenging to
implement. preventive vaccines could important clinical impact,
especially among children younger 3 years old susceptible to
the neurological complications. several groups highly affected
asia-pacific region working towards vaccines ev71 candidates
have progressed late-stage clinical trials two vaccines recently reported
to approved regulatory authorities china. report
summarizes current issues progress development vaccines against
ev71.

copyright Â© 2016 world health organization. published elsevier ltd.. all
rights reserved.

doi: 10.1016/j.vaccine.2016.02.077 
pmid: 26973065  [indexed medline]

